Apnimed, Inc. Common Stock APMD
$26.22
-9.59%
at last close
Market Cap$1.09 billion
P/E Ratio—
Div Yield—
Volume1.51M
52-Week Range
$16.12$35.29
Analyst Ratings
- Consensus
- Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $50.33 (+92.0% upside)
Key Stats
- Today's Range
- $23.13 – $28.90
- 50-Day Range
- $16.12 – $35.29
- 52-Week Range
- $16.12 – $35.29
- Volume
- 1.51 million shs
- Average Volume
- 491K shs
- Market Cap
- $1.09 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.98%
- Days to Cover
- 1.00
About Apnimed, Inc. Common Stock
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Related Stocks
Compare head-to-head: APMD vs LLY·APMD vs JNJ·APMD vs ABBV·APMD vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.